Tag: Clots
Review Supports LMWH for Cancer-Linked Incidental PE
VTE recurrence risk similar under LMWHs, vitamin K antagonists; risk of major hemorrhage up under VKA
FDA Approves Coagadex for Rare Clotting Disorder
First coagulation therapy sanctioned for Factor X deficiency
FDA Approves Praxbind to Reverse Pradaxa’s Effect
Praxbind cleared for emergency use with Pradaxa when bleeding can't be controlled
Subclavian Vein Catheterization Beats Jugular, Femoral Placement
Reduces risk of blood infection, deep-vein thrombosis among critically ill
Anticoagulation Report Has Little Impact in Discharge Summary
Safe Transitions Anticoagulation Report has no impact on clinical outcomes for patients on warfarin
Bivalirudin Doesn’t Lower Major Cardiovascular Event Rate in ACS
No decrease in rate of major CV events, net adverse clinical events for patients undergoing PCI
Periop Bridging Unnecessary for Most A-Fib Patients on Warfarin
Arterial thromboembolism risk doesn't appear to rise without additional drug treatment
Peripherally Inserted Central Catheters Up VTE Risk
In hospitalized patients, increased risk of upper- and lower-extremity deep vein thrombosis
Full-Dose Tinzaparin Doesn’t Cut Risk of Recurrent VTE in CA
No difference in major bleeding, overall mortality, but reduction in clinically relevant nonmajor bleeding
Guideline-Based Protocol Ups Adherence to VTE Prophylaxis
Significantly more patients receive VTE prophylaxis after implementation of guideline-based protocol
